Case Report: Neuroendocrine Breast Carcinoma with a Germline EGFR T790M Mutation

Overview

Journal Front Oncol

Specialty Oncology

Date 2023 Jun 2

PMID 37265791

Authors

Olivia A Sagan

Anna Rothstein

Bhaghyasree Jambunathan

Mersiha Hadziahmetovic

Anita Antoniolli

M Hammad Rashid

Affiliations

Soon will be listed here.

Abstract

Background: The epidermal growth factor receptor (EGFR) p.Thr790Met (T790M) mutation was discovered as a resistance mechanism in patients with lung cancer treated with first- and second-generation tyrosine kinase inhibitors. Further studies revealed the EGFR T790M mutation in treatment-naive non-small cell lung carcinoma (NSCLC) and as a rare germline mutation strongly associated with NSCLC. Somatic EGFR T790M mutations have been reported in a limited population of patients with triple-negative breast cancer. There are no previous reports of a germline EGFR T790M mutation found in a patient with breast cancer.

Case Presentation: We present a rare case of a 42-year-old woman with a rapidly progressing 8 cm mass in the right lateral breast. An additional right breast mass with multiple lymph nodes characteristic or suspicious of metastasis was found. Ultrasound-guided biopsy showed high-grade, poorly differentiated invasive neuroendocrine carcinoma of the right breast and metastatic carcinoma of a right axillary lymph node. Genetic testing revealed a germline EGFR T790M mutation. The patient underwent neoadjuvant chemotherapy, right mastectomy with lymph node dissection, adjuvant radiation to the right chest wall and axilla, and adjuvant chemotherapy.

Conclusion: This is the first reported case of a patient with high-grade neuroendocrine carcinoma, triple-negative breast cancer and a germline EGFR T790M mutation. Further investigation is needed to find a possible correlation between the cancer in this patient and her mutation. Since there are no current guidelines, further research is also needed to define screening protocols for patients with germline EGFR T790M mutations. Additional treatment options and cancer risk could also be found with further research, which would benefit all patients with a germline EGFR T790M mutation.

Citing Articles

Primary neuroendocrine tumor of the breast: A case report.

Ju H, Liu M Oncol Lett. 2024; 29(2):79.

PMID: 39655273 PMC: 11626422. DOI: 10.3892/ol.2024.14825.

References

Lou Y, Pecot C, Tran H, DeVito V, Tang X, Heymach J . Germline Mutation of T790M and Dual/Multiple EGFR Mutations in Patients With Lung Adenocarcinoma. Clin Lung Cancer. 2015; 17(2):e5-11. PMC: 5119523. DOI: 10.1016/j.cllc.2015.11.003. View

Sun H, Dai S, Xu J, Liu L, Yu J, Sun T . Primary Neuroendocrine Tumor of the Breast: Current Understanding and Future Perspectives. Front Oncol. 2022; 12:848485. PMC: 9174548. DOI: 10.3389/fonc.2022.848485. View

Yu H, Arcila M, Rekhtman N, Sima C, Zakowski M, Pao W . Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res. 2013; 19(8):2240-7. PMC: 3630270. DOI: 10.1158/1078-0432.CCR-12-2246. View

Shi Y, Li J, Zhang S, Wang M, Yang S, Li N . Molecular Epidemiology of EGFR Mutations in Asian Patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology - Mainland China Subset Analysis of the PIONEER study. PLoS One. 2015; 10(11):e0143515. PMC: 4657882. DOI: 10.1371/journal.pone.0143515. View

Ramlau R, Cufer T, Berzinec P, Dziadziuszko R, Olszewski W, Popper H . Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer in the Real-World Setting in Central Europe: The INSIGHT Study. J Thorac Oncol. 2015; 10(9):1370-1374. DOI: 10.1097/JTO.0000000000000621. View

Ozdirik B, Kayser A, Ullrich A, Savic L, Reiss M, Tacke F . Primary Neuroendocrine Neoplasms of the Breast: Case Series and Literature Review. Cancers (Basel). 2020; 12(3). PMC: 7140078. DOI: 10.3390/cancers12030733. View

Maheswaran S, Sequist L, Nagrath S, Ulkus L, Brannigan B, Collura C . Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med. 2008; 359(4):366-77. PMC: 3551471. DOI: 10.1056/NEJMoa0800668. View

Mok T, Wu Y, Thongprasert S, Yang C, Chu D, Saijo N . Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361(10):947-57. DOI: 10.1056/NEJMoa0810699. View

Tibaldi C, Giovannetti E, Vasile E, Boldrini L, Gallegos-Ruiz M, Bernardini I . Inherited germline T790M mutation and somatic epidermal growth factor receptor mutations in non-small cell lung cancer patients. J Thorac Oncol. 2011; 6(2):395-6. DOI: 10.1097/JTO.0b013e3182059a6f. View

10.

Bhargava R, Gerald W, Li A, Pan Q, Lal P, Ladanyi M . EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations. Mod Pathol. 2005; 18(8):1027-33. DOI: 10.1038/modpathol.3800438. View

11.

Savelli G, Zaniboni A, Bertagna F, Bosio G, Nisa L, Rodella C . Peptide Receptor Radionuclide Therapy (PRRT) in a Patient Affected by Metastatic Breast Cancer with Neuroendocrine Differentiation. Breast Care (Basel). 2014; 7(5):408-10. PMC: 3518936. DOI: 10.1159/000343612. View

12.

Oxnard G, Miller V, Robson M, Azzoli C, Pao W, Ladanyi M . Screening for germline EGFR T790M mutations through lung cancer genotyping. J Thorac Oncol. 2012; 7(6):1049-52. PMC: 3354706. DOI: 10.1097/JTO.0b013e318250ed9d. View

13.

Yu H, Arcila M, Fleischut M, Stadler Z, Ladanyi M, Berger M . Germline EGFR T790M mutation found in multiple members of a familial cohort. J Thorac Oncol. 2014; 9(4):554-8. PMC: 4412273. DOI: 10.1097/JTO.0000000000000052. View

14.

Weeber F, Cirkel G, Hoogstraat M, Bins S, Gadellaa-van Hooijdonk C, Ooft S . Predicting clinical benefit from everolimus in patients with advanced solid tumors, the CPCT-03 study. Oncotarget. 2017; 8(33):55582-55592. PMC: 5589684. DOI: 10.18632/oncotarget.16029. View

15.

Russo A, Franchina T, Ricciardi G, Picone A, Ferraro G, Zanghi M . A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives. Oncotarget. 2015; 6(29):26814-25. PMC: 4694955. DOI: 10.18632/oncotarget.4254. View

16.

Hu Y, Alden R, Odegaard J, Fairclough S, Chen R, Heng J . Discrimination of Germline T790M Mutations in Plasma Cell-Free DNA Allows Study of Prevalence Across 31,414 Cancer Patients. Clin Cancer Res. 2017; 23(23):7351-7359. PMC: 5712272. DOI: 10.1158/1078-0432.CCR-17-1745. View

17.

Cross D, Ashton S, Ghiorghiu S, Eberlein C, Nebhan C, Spitzler P . AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014; 4(9):1046-61. PMC: 4315625. DOI: 10.1158/2159-8290.CD-14-0337. View

18.

Vranic S, Palazzo J, Sanati S, Florento E, Contreras E, Xiu J . Potential Novel Therapy Targets in Neuroendocrine Carcinomas of the Breast. Clin Breast Cancer. 2018; 19(2):131-136. DOI: 10.1016/j.clbc.2018.09.001. View

19.

Reis-Filho J, Pinheiro C, Lambros M, Milanezi F, Carvalho S, Savage K . EGFR amplification and lack of activating mutations in metaplastic breast carcinomas. J Pathol. 2006; 209(4):445-53. DOI: 10.1002/path.2004. View

20.

Barker A, Gibson K, Grundy W, Godfrey A, Barlow J, Healy M . Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. Bioorg Med Chem Lett. 2001; 11(14):1911-4. DOI: 10.1016/s0960-894x(01)00344-4. View